|
Alpha Teknova Inc
TKNO's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Alpha Teknova Inc 's sales fell
by -30.12 % in III. Quarter 2023 from the same quarter a year ago.
Ranking at No. 2966
In Vitro & In Vivo Diagnostic Substances industry recorded
growth of revenues by 11.11 %
Alpha Teknova Inc net loss decreased from $-22 millions, to $-10 millions in III. Quarter 2023,
• More on TKNO's Growth
|
|
Alpha Teknova Inc realized a net loss in trailing twelve months.
Alpha Teknova Inc realized cash reduction of $ -0.59 per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.26.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.27.
• More on TKNO's Valuation
|
|
|
|
|
Alpha Teknova Inc realized net loss in trailing twelve months.
Alpha Teknova Inc realized cash outflow of $ -0.59per share in trailing twelve-month period. In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 4.26.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 8.27.
Alpha Teknova Inc Price to Book Ratio is at 1.52 lower than Industry Avg. of 411.78. and higher than S&P 500 Avg. of 0
• More on TKNO's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com